🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Koji Izutsu

National Cancer Centre Japan

ORCID: 0000-0001-9129-8057

Also affiliated with National Cancer Center, National Cancer Center Hospital East, Tokyo National Hospital, Toranomon Hospital, National Cancer Research Institute

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2”.

PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2

Hematological Oncology(2023)10.1002/hon.3166_ot28

N/A

0DataRank · unranked

6 citations

Martine E.D. Chamuleau, Georg Lenz, Michael Roost Clausen, Corinne Haïoun, Koji Izutsu +11 more

Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study

Blood(2023)10.1182/blood-2023-186145

N/A

0DataRank · unranked

0 citations

Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Lindsey E. Roeker, Krish Patel +17 more

142 | LISOCABTAGENE MARALEUCEL IN R/R FL (TRANSCEND FL): IMPACT OF PRIOR LINES OF THERAPY, BENDAMUSTINE EXPOSURE, AND DISEASE PROGRESSION ≤ 24 MONTHS OF INITIAL SYSTEMIC THERAPY

Hematological Oncology(2025)10.1002/hon.70093_142

N/A

0DataRank · unranked

0 citations

Juan Luis Reguera Ortega, Franck Morschhauser, Guillaume Cartron, Aaron P. Rapoport, Koji Izutsu +14 more